secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nabriva Therapeutics plc (—)
CIK:        0001641640
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001104659-23-083250
Event type: regulatory
Sentiment:  negative
Materiality: 0.95
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nabriva receives Nasdaq delisting notice; trading to suspend Aug 1, 2023
------------------------------------------------------------------------

- Stockholders' equity deficit of $(4,357,000) as of March 31, 2023 fails $2.5M minimum under Rule 5550(b)(1).
- Nasdaq will suspend trading at open on August 1, 2023; Company will not appeal.
- Ordinary shares may become eligible for Pink Open Market quotation, but no assurances given.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641640/000110465923083250/0001104659-23-083250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641640/000110465923083250/tm2321842d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-083250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer